Bimatoprost

Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024May 24, 2024 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, convenes an ordinary shareholder meeting on Friday June 28th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.The documents mentioned in article R.22.10-23 of the French Code de commerce, including a proxy voting form, will be sent to the shareholders upon written request. These documents will also be made available to shareholders at the headquarters of the Company and on its website (www.nicox.com) by June 13th, 2024.Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company’s website. Shareholders may also contact the Company’s Investor Relations team at ag2024nicox@nicox.com for any question on the voting process.In the event the quorum is not reached on first call, Nicox will convene an ordinary shareholder meeting on a second call on Monday July 15th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageBryan, Garnier & Co Eric Yoo Paris, FranceH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive Officer+33 (0)4 97 24 53 00communications@nicox.com Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.comNicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_OGM June 2024_Annoucement

Press Release Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary General Meetings May 6, 2024 – release at 17h45 CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, announced that the Ordinary and Extraordinary General Meetings were held today, on second convening.The general meetings were held in the presence of SCP EZAVIN-THOMAS, in the person of Maître Nathalie Thomas, in their capacity as ad hoc agent to represent non-voting shareholders at the general meetings. SCP EZAVIN-THOMAS was appointed by order of the President of the Commercial Court of Antibes in a second decision on April 25, 2024, in replacement of SELARL XAVIER HUERTAS & ASSOCIES, in the person of Maître Xavier Huertas, initially appointed by the President of the Commercial Court of Antibes on April 18, 2024.Including the presence of Maître Nathalie Thomas, in accordance with the terms of the orders of the President of the Commercial Court of Antibes of the April 18 and 25 2024, the quorum, which was initially at 18,73% was brought to 100% of the shares eligible to vote.The shareholders of Nicox adopted the ordinary and extraordinary resolution proposed by the Board of Directors, notably: The ratification of the transfer of the registered office to Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois, 06410 Biot;The reduction of the share capital due to losses by reducing the nominal value of the shares from €1 to €0.01;the financial authorisations granted to the Board of Directors to carry out capital increases with or without preferential subscription rights;the authorization given to the Board of directors to grant free shares and/or stock options to the Company's employees and corporate officers;Resolutions relating to the agreement with BlackRock Inc. (cf press release of February 28, 2024), namely: the appointment of Mrs. Sonia Benhamida and Mr. Maurizio Petitbon as observers;the authorisation granted to the Board of Directors to issue bonds convertible into shares. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageBryan, Garnier & Co Eric Yoo Paris, FranceH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive Officer+33 (0)4 97 24 53 00communications@nicox.com Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.comNicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_EGM May 2024_Results_Second_Convocation_PR_V1